Please assess the completion status of the following clinical trial:

Trial Title: Schedules of Nab-Paclitaxel in Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed HER2-negative metastatic (stage IV) breast cancer.~* Measurable or non-measurable, but radiologically evaluable, disease according to RECIST 1.1 criteria.~* Female aged 18 years or older.~* Life expectancy \> 3 months.~* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.~* Either ER-positive or ER-negative disease. Patients with ER-positive disease must be endocrine resistant, defined as having failed at least one prior endocrine therapy for breast cancer, or must be candidates for first-line chemotherapy.~* If previously treated with a taxane or anthracycline in the neoadjuvant or adjuvant setting, the period from end of treatment to disease recurrence must have been \> 12 months (\> 365 days).~* Radiation therapy, if given and regardless of site, must be completed at least 2 weeks prior to randomization.~* Normal hematologic status.~* Normal renal function.~* Normal liver function.~* Normal cardiac function.~* Women of childbearing potential: documented negative pregnancy test within 2 weeks prior to randomization, and acceptable birth control during the duration of the trial therapy and for a period of 6 months following the last administration of study drug.~* Written Informed Consent (IC) must be signed and dated by the patient and the Investigator prior to randomization.~* Completed baseline Quality of Life Form.~* The patient has been informed of and agrees to data transfer and handling, in accordance with national data protection guidelines.~* Availability of an formalin fixed paraffin embedded (FFPE) block from the primary tumor (breast lesion) for submission to central pathology review and for translational research.~* Written consent to pathology material submission, signed and dated by the patient and the Investigator prior to randomization.~Exclusion Criteria:~* Any prior chemotherapy for metastatic breast cancer.~* Presence of central nervous system (CNS) metastasis.~* Peripheral neuropathy grade 2 or higher (CTCAE version 4).~* Significant uncontrolled cardiac disease (i.e. unstable angina, recent myocardial infarction within prior 6 months), patients classified as having a New York Heart Association (NYHA) class III or IV congestive heart failure.~* Pregnant or lactating.~* Prior history of non-breast malignancy (except for adequately controlled basal cell carcinoma of the skin, carcinoma in situ of the cervix, in situ carcinoma of the bladder).~* Any concurrent condition which in the Investigator's opinion makes it inappropriate for the patient to participate in the trial or which would jeopardize compliance with the protocol.~* Contraindications or known hypersensitivity to the study medication or excipients.~* The use of any anti-cancer investigational agents within 30 days prior to expected start of trial treatment.~* Inability or unwillingness to abide by the study protocol or cooperate fully with the Investigator.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A: nab-Paclitaxel 150 mg/m2 days 1,15 (Type: EXPERIMENTAL): Arm A: Induction\* nab-Paclitaxel 125 mg/m2 on days 1,8,15 every 28 days for 3 cycles followed by maintenance nab-Paclitaxel 150 mg/m2 administered on days 1, 15 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity.~\*Following Amendment 1, the dose in the induction phase dose in all three arms was reduced to 125 mg/m² from 150 mg/m².
- B: nab-Paclitaxel 100 mg/m2 days 1,8,15 (Type: EXPERIMENTAL): Arm B: Induction\* nab-Paclitaxel 125 mg/m2 on days 1,8,15 every 28 days for 3 cycles followed by maintenance nab-Paclitaxel 100 mg/m2 administered on days 1, 8, 15 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity.~\*Following Amendment 1, the dose in the induction phase dose in all three arms was reduced to 125 mg/m² from 150 mg/m².
- C: nab-Paclitaxel 75 mg/m2 days 1,8,15,22 (Type: EXPERIMENTAL): Arm C: Induction\* nab-Paclitaxel 125 mg/m2 on days 1,8,15 every 28 days for 3 cycles followed by maintenance nab-Paclitaxel 75 mg/m2 administered on days 1, 8, 15, 22 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity.~\*Following Amendment 1, the dose in the induction phase dose in all three arms was reduced to 125 mg/m² from 150 mg/m².

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete